Market
Percentage of global HIV infections prevented by new injections by end of 2025?
1
Resolution / Starting Odds
Less than 10% • 25%
10% to 20% • 25%
21% to 30% • 25%
More than 30% • 25%
Global health reports and studies published by organizations like UNAIDS
Story
New HIV Prevention Injections Offer Six Months Protection; 100% Effective, Gilead to Sell Generics Ahead of World AIDS Day
Dec 1, 2024, 04:00 PM
Recent advancements in HIV prevention include long-acting injections that provide protection for up to six months per shot. As World AIDS Day approaches, experts are evaluating the implications of these new tools in combating HIV. A study has shown that a twice-yearly injection was 100% effective in preventing HIV infections among women and nearly as effective in men. Pharmaceutical company Gilead has announced plans to sell affordable generic versions of the medication in 120 countries with high rates of HIV. Despite these advancements, experts emphasize the importance of equitable access and addressing adherence challenges to maximize the impact of HIV prevention efforts.
View original story
Similar markets
20% to 30% • 25%
More than 30% • 25%
Less than 10% • 25%
10% to 20% • 25%
Reduction by 5% to 10% • 25%
Reduction by 10% to 15% • 25%
Reduction by more than 15% • 25%
Reduction by less than 5% • 25%
10% to 20% • 25%
20% to 30% • 25%
Less than 10% • 25%
More than 30% • 25%
Approved in UK and EU • 25%
Not approved in any major market • 25%
Approved in UK, EU, and USA • 25%
Approved in UK only • 25%
Less than 50% • 25%
70% to 90% • 25%
50% to 70% • 25%
More than 90% • 25%
Neither dominates • 25%
Lenacapavir • 25%
Cabotegravir • 25%
Both equally • 25%
50% to 75% • 25%
100% or more • 25%
Less than 50% • 25%
76% to 99% • 25%
More than 60% • 25%
Less than 20% • 25%
20% to 40% • 25%
40% to 60% • 25%
